SlideShare a Scribd company logo
1 of 58
Turning Off the Faucet from Above:
Health Plan Involvement
in Safe Prescribing
Presenters:
• Roneet Lev, MD, Director of Operations, Scripps Mercy Hospital Emergency
Department, and Chair, San Diego County (CA) Rx Drug Abuse Medical Task
Force
• Daniel Calac, MD, FAAP, Chief Medical Officer, Indian Health Council, Inc.
• Margaret Mendes, PharmD, Program Director, Academic Detailing Service, VA
Desert Pacific Healthcare Network
• George Scolari, Behavioral Health Program Manager, Community Health Group
Third-Party Payer Track
Moderator: Mark D. Birdwhistell, MPA, Vice President for
Administration and External Affairs, University of Kentucky HealthCare
Disclosures
Daniel Calac, MD, FAAP; Roneet Lev, MD;
Margaret Mendes, PharmD; George Scolari; and
Mark D. Birdwhistell, MPA, have disclosed no
relevant, real, or apparent personal or
professional financial relationships with
proprietary entities that produce healthcare
goods and services.
Disclosures
• All planners/managers hereby state that they or their
spouse/life partner do not have any financial
relationships or relationships to products or devices
with any commercial interest related to the content of
this activity of any amount during the past 12 months.
• The following planners/managers have the following to
disclose:
– John J. Dreyzehner, MD, MPH, FACOEM – Ownership
interest: Starfish Health (spouse)
– Robert DuPont – Employment: Bensinger, DuPont &
Associates-Prescription Drug Research Center
Learning Objectives
1. Describe strategies to engage health plans in
safe prescribing efforts.
2. Identify some red flag medications and
combinations that are key to safe prescribing.
3. Outline some health plan policies that can be
used for safe prescribing.
4. Provide accurate and appropriate counsel as
part of the treatment team.
Roneet Lev, MD, Director of Operations, Scripps Mercy Hospital San Diego
Chair, San Diego Prescription Drug Abuse MedicalTask Force
DanielCalac, MD, Chief Medical Officer, Indian Health Council, Inc
Margaret Mendes Pharm D, Program Director,VA San Diego Healthcare System
George Scolari, Behavioral Health Program Manager,Community Health Group
VA Health Care
The San Diego Medical Task Force and Death Diaries
Community Health Group
1
3
4
2 Indian Health Council
5 Health Plan Recommendations
San Diego Death Diaries
Medical Examiner and PDMP
Data Results
 Facilitator
 DEA
 Emergency Physicians
 Primary Care
 Pain Management
 Addiction Specialists
 PharmacyAssociation
 HospitalAssociation
 Dental Association
 PsychiatricAssociation
 Pediatric Association
 Kaiser
 Scripps
 Sharp
 Community Clinics
 VA
 Military
 Palomar Pomerado
 Indian Health
 Methadone Clinic
 ME Data
• 254 deaths with
prescriptions as cause of
death
• Could be with alcohol, illicit,
over the counter
 PDMP Data
• Does Not Include
 VA
 Balboa Naval Hospital
 Methadone Clinics
 Inpatient hospitals
186
68
254 Prescription Related Deaths
in San Diego 2013
CURES Data
No CURES
10
20%
80%
Single Medication (51)
Multiple Medication (203)
11
2.8
1.6
68.8
0
10
20
30
40
50
60
70
80
California San Diego San Diego Deaths
2013 Census 38.3 million 3.2 million 254
Patients with Rx 7,057,000 816,372 186
Chronic Use 200,080 13,567 128
12
PDMP Match (3)
6%
PDMP Match + Doctor
Shopper (3)
7%
PMDP Match + Doctor
Shopper + Illicit (1)
2%
No Recent
Methadone Rx (3)
7%
No Methadone on
PDMP (24)
52%
No PDMP Data (12)
26%
PDMP Match (3)
PDMP Match + Doctor Shopper
(3)
PMDP Match + Doctor Shopper
+ Illicit (1)
No Recent Methadone Rx (3)
No Methadone on PDMP (24)
 46 deaths
 Number One drug to cause a single medication related death
 85% (39) of Deaths Rx from outside PDMP system
 100% deaths (7) from PDMP system from primary care
 All PDMP Reports – 54% (100 patients)
 ME Deaths – 21% (55)
39
16
Opioids + Benzodiazepines
ME Reports – 55 patients
PDMP Match
No Match
100
86
PDMP Reports with
Opioid + Benzodiazepine
Combination
Opioid + Benzo
No Combination
13
 52 Patients (28% of all PDMP Reports)were Doctor
Shoppers
 “The Heavy Half” = Received 51% of all Rx
 50/50 Male/Female
28%
72%
% Doctor Shoppers
Doctor Shopper
Regular Patient
14
 Emergency Department Guidelines
 Urgent Care Guidelines
 Medication Agreements
 Treatment Guidelines
 Interdisciplinary Conferences
 Educational Outreach
 Magazine Publications
 Case Discussions
 Media Outreach
 Further Research
 Medical Examiner Feedback to Physicians
 Lev, R et al “A description of Medical Examiner prescription –related
deaths and prescription drug monitoring program data” American
Journal of Emergency Medicine. December 2015.
 Lev, R et al “Methadone Deaths Compared to All Prescription Related
Deaths” Forensic Science International.2015
 Lev, R et al “Who is prescribing controlled medications to patients who
die from prescription drug abuse?” AmericanJournal of Emergency
Medicine.Oct 2015.
16
SanDiegoRxAbuseTaskForce.Org
Daniel Calac, MD
Chief Medical Officer
Indian Health Council, Inc
Funded by the National Institutes
for Health and the Indian Health
Service
RINCON SITE SANTAYSABEL SITE
Study Goal: to reduce availability and misuse of
prescription pain pills in a rural tribal community
Hypotheses: To use focused community interventions to:
 1) Create convenient options for community members to reduce
availability of non-prescribed use;
 2) Demonstrate feasibility of a culturally tailored and environmentally
sound drug disposal system in American Indian communities; and
 3) Change norms around giving away one’s prescription pain pills to
family members or friends.
 Created in 2008 to address rising prescription
pain medication misuse/abuse
 Use a multidisciplinary approach which
addresses the physical, psychological and
social issues associated with chronic pain
conditions
 Hold patient and provider accountable for use of
opioid medications for chronic health
 Updated prescribing practices and
policies in IHC medical manual
 Implement a Pain Agreement
 Conduct a initial assessment
▪ Formulate a treatment plan
 Treatment plan includes other modalities
▪ Acupuncture, group therapy, chiropractics,
physical therapy, nutrition education
 Set a maximum number of 200mg pill/month
of any one opioids; set a maximum daily
morphine equivalent dosage at 200mg
 Conduct Urine Drug Screens
 Conduct a CURES report
 Administer pain questionnaires
Conduct initial
evaluation
• History and physical examination
• Lab work ordered
• Screen for abuse potential using SOAAP-R
• Run CURES report to check for recent opioid activity elsewhere
Pain
Agreement
• Provider creates a plan that includes other modalities
• Acupuncture, group therapy, chiropractics, physical therapy, nutrition education
• Patient and provider sign agreement, and a copy of the agreement is given to the patient
• Patient conducts additional assessments with other modalities
Follow up
• At subsequent visits, patient leaves a urine specimen for a drug screen
• Pain questionnaire
• Review Pain Agreement
 Training IHC providers on safe prescribing
 No longer prescribing soma (Carisoprodol)
 Limit opioid formulary to MS Contin,
Oxycontin, combination analgesics
 Interviewing tribal leaders about prescription drug
disposal practices and barriers to implementation
 Conducting focus groups on disposal methods
 Conducting pill take-back events
 Establishing permanent drop-boxes
 Daniel Calac, MD, dcalac@indianhealth.com
 Tony Luna, MA, tluna@indianhealth.com
 Roland Moore, PhD, roland@prev.org
 Rick Mcgaffigan, MA, rmcgaffigan@prev.org
Margaret Mendes, Pharm.D.
Director, VISN 22 Academic Detailing Service
 Discuss risks with opioids and benzodiazepines
 RecognizeVeteran patients at increased risk
 DescribeVA policies and processes to reduce combination
 Show success inVA
 Discuss future education on benzodiazepine safety
33
 After opioids, benzodiazepines are drug class most commonly involved
in pharmaceutical OD deaths (30%) 1
 In the general population benzodiazepines are class most commonly
involved in an opioid-related death (30%) 1
 In theVA, 50% of opioid OD deaths are on concurrent
benzodiazepines2
 Among opioid users, risk of death goes up with benzodiazepines in a
dose-response fashion
1. Jones CM, et al. JAMA 2013;309 (70):657-659.
2. Park TW, et al. BMJ. 2015;350:h2698.
0
10
20
30
40
50
60
70
Opioid
prescription
Highest
quintile of
avg daily
opioid use
Duration of
opioid use >2
months
Concurrent
opioids
Concurrent
sedative
hypnotics
Early opioid
refills
Percent(%)
No MH diagnosis MH diagnosis w/o PTSD PTSD
JAMA 2012; 307:940-7
Veterans are twice as likely to die from accidental overdose compared to
the non-Veteran population
 Assessment of risk factors is important in ourVeteran population
especially in returning combatVeterans
 Psychological distress may lead to inappropriate use of opioid
medications
 Caution should be used in this population
Bohnert AS, et al. Med Care 2011;49: 393–396
VISN 22 Network Policy N.:2015-05: Chronic Opioid Use for Non-Malignant Pain
 Education on risks of
overdose
 Offer naloxone kits to
patients at risk of
overdose
 Patient resistance
 Provider resistance
 Visit time constraints and follow up
 Different prescribers of the medications
 Primary Care – Opioids
 Mental Health – Benzodiazepines
 Benzodiazepines in the elderly
 Associated with significant risks: falls1, hip fractures2,3,4, sedation1,
CI,1,5,6 MVA7,8, OD9,10
 Benzodiazepines in dementia
 Generally not recommended due to side effects. Lorazepam and
oxazepam do not require oxidative metabolism in the liver and have
no active metabolites therefore many clinicians prefer these agents.11
 Benzodiazepines in PTSD
 No efficacy to support core symptoms. Cognitive effects are
concerning.12
 Insomnia education
 50% increase in overall mortality rates associated with long-term
benzodiazepine use.13
 Promoting non-pharmacological treatment first
 Cognitive BehavioralTherapy (CBT), CBT for Insomnia, relaxation
therapy, supportive therapy
1. Glass J, et al. BMJ. 2005;331(7526):1169.
2. Ray WA, et al. JAMA. 1989. 262(23):3303-3307.
3. Wang PS, et al. Am J Psychiatry. 2001;158(6):892-8.
4. Chang CM, et al. Am J Geriatr Psychiatry. 2008;16(8):686-92.
5. Paterniti S, et al. J Clin Psychopharmacol. 2002;22(3):285-93.
6. Billoti de Gage S, et al. BMJ. 2012. 345:e6231.
7. Ray WA, et al. Am J Epidemiology.1992;136(7):873-83.
8. Hemmelgarn B, et al. JAMA. 1997;278(1):27-31.
9. Jones CM, et al. JAMA 2013;309(70):657-659.
10. ParkTW, et al. BMJ. 2015;350:h2698.
11. Rabins PV, et al. APA Practice Guideline forTreatment of Patients with Alzheimer’s
Disease and other dementias.
12. VA/DoD 2010 Practice Guidelines for Management of PTSD. www.healquality.va.gov
13. Kripke DF, et al. 2012 BMJ open 2 , e000850.
George Scolari, Behavioral Health Program Manager
Community Health Group
Chair, Healthy San Diego Behavioral HealthWork Group
 Formed in 1998, Healthy San Diego is the
umbrella in which 5 Medicaid (Medi-Cal)
Managed Care Plan’s operate in San Diego.
 Care1st, Community Health Group, Health Net,
Kaiser Permanente & Molina Healthcare.
 The Healthy San Diego Behavioral Health Work
Group was formed in 1998 when Specialty
Mental Health was contractually carved out of
Medi-Cal Managed Care Plans in California.
 Dr. Roneet Lev, Chair of the San Diego
Prescription Drug Abuse MedicalTask Force,
presented “San Diego Death Diaries” to
Community Health Group’s Pharmacy and
Therapeutics Committee Meeting.
 The Committee elected to look at “Red Flag”
medications and combinations within
Community Health Group’s utilization data.
 HolyTrinity (opioid, benzodiazepine, and
carisoprodol)
 Benzodiazepines Plus Opioids
 Soma (carisoprodol)
 Ambien (Zolpidem) – long term
 Xanax – long term
 Long Acting Opioids – by ED provider
 Methadone – by Primary Care
 Community Health Group is in the process of
implementing a pain management specialty
restriction on methadone prescriptions.
 CHG’s Chief Medical Officer and Pharmacy Director
had a conversation with an “outlier” prescriber who is
not a pain management specialist.
 CHG’s P&T voted to remove Soma from formulary.
 Safe Prescribing Guide developed by the Healthy San
Diego Behavioral HealthWork Group.
 Chronic, non-cancer pain management
by pain management specialists or in
consultation with pain management
specialists
 Prior authorization and utilization
management edits such as:
 Quantity and fill limits,
 Formulary management,
 Provider restrictions
 Concurrent use edits.
 Use of treatment plans to include
assessment of pain; treatment modalities
considered, tried, failed; treatment goals;
medication necessary to manage pain.
 Use of a pain contract between prescriber
and member.
 Restrict members to one prescriber.
 Restrict members to one pharmacy.
 Random drug screens.
 Regular review of utilization management
reports based on members, prescribers,
and pharmacies.
 Recommend providers check CURES.
 Review utilization of the “HolyTrinity” use among
CHG members.
 Review data by prescribers.
 Address utilization with “outliers”.
 Work on utilization management edits – will have to
address strategically since this is likely to affect
many providers and members.
 Collaborate with other San Diego Medi-Cal
Managed Care Plan’s (Healthy San Diego) .
Promote PDMP Use Promote Utilization of Drug Screens
Use Medication Agreements
Education
Formulary Changes
Prior Authorization
Provider Restriction
Alternate PainTreatment Modality
Join One San DiegoVision
One Provider,One Pharmacist
Use CURES (PDMP)
MedicationAgreement
No Opioid + Benzodiazepines
Honor EmergencyGuidelines
 Benzodiazepine plus Opioids – avoid combination
 Soma (Carisoprodol) – off formulary
 Methadone– restricted provider
 Xanax – non formulary
 High Dose Morphine Equivalent- prior authorization for
new start > 90 MME
 New Start Opioids – prior authorization for > 2-3 months
 Acute Prescriptions – limit to 30 tablets
 Feedback to providers after EmergencyVisit
 Federal
 Patient Satisfaction is Obstacle to Safe Prescribing
 Do not link money with satisfaction scores for doctors
 CURES gold standard: Universal, RealTime, Actively Managed
 State
 Data comparison for state
 Education Databank
 Law enforcement allowed to assist with court mandated
rehabilitation, allow PDMP access
 Pain CME, not biased towards pharmaceutical
 Local
 Health Plan Best Practices
 Feedback from Medical Examiner to Provider
 Pediatrician involved in prevention
 Unified Media Message
Turning Off the Faucet from Above:
Health Plan Involvement
in Safe Prescribing
Presenters:
• Roneet Lev, MD, Director of Operations, Scripps Mercy Hospital Emergency
Department, and Chair, San Diego County (CA) Rx Drug Abuse Medical Task
Force
• Daniel Calac, MD, FAAP, Chief Medical Officer, Indian Health Council, Inc.
• Margaret Mendes, PharmD, Program Director, Academic Detailing Service, VA
Desert Pacific Healthcare Network
• George Scolari, Behavioral Health Program Manager, Community Health Group
Third-Party Payer Track
Moderator: Mark D. Birdwhistell, MPA, Vice President for
Administration and External Affairs, University of Kentucky HealthCare

More Related Content

What's hot

Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiroWeb only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiroOPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
 
Rx16 federal tues_1115_1_fretwell_2gabbert-wilkebrown
Rx16 federal tues_1115_1_fretwell_2gabbert-wilkebrownRx16 federal tues_1115_1_fretwell_2gabbert-wilkebrown
Rx16 federal tues_1115_1_fretwell_2gabbert-wilkebrownOPUNITE
 
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonaldRx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonaldOPUNITE
 
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4travenRx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4travenOPUNITE
 
Rx16 clinical tues_330_1_lindroth_2okeson
Rx16 clinical tues_330_1_lindroth_2okesonRx16 clinical tues_330_1_lindroth_2okeson
Rx16 clinical tues_330_1_lindroth_2okesonOPUNITE
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioOPUNITE
 
Rx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenRx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenOPUNITE
 
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonickRx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonickOPUNITE
 
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosalesRx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosalesOPUNITE
 
Rx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_groupRx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_groupOPUNITE
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynoteOPUNITE
 
Rx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisherRx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisherOPUNITE
 
Rx16 vs ama_tues_800_harris
Rx16 vs ama_tues_800_harrisRx16 vs ama_tues_800_harris
Rx16 vs ama_tues_800_harrisOPUNITE
 
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranRevised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranOPUNITE
 
Rx16 federal visionsession_200
Rx16 federal visionsession_200Rx16 federal visionsession_200
Rx16 federal visionsession_200OPUNITE
 
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverRx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverOPUNITE
 
Rx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3greenRx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3greenOPUNITE
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_finalOPUNITE
 
Rx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3greenRx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3greenOPUNITE
 

What's hot (20)

Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiroWeb only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Rx16 federal tues_1115_1_fretwell_2gabbert-wilkebrown
Rx16 federal tues_1115_1_fretwell_2gabbert-wilkebrownRx16 federal tues_1115_1_fretwell_2gabbert-wilkebrown
Rx16 federal tues_1115_1_fretwell_2gabbert-wilkebrown
 
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonaldRx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
Rx16 treat tues_330_1_mcneely_2d_onofrio_3macdonald
 
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4travenRx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
 
Rx16 clinical tues_330_1_lindroth_2okeson
Rx16 clinical tues_330_1_lindroth_2okesonRx16 clinical tues_330_1_lindroth_2okeson
Rx16 clinical tues_330_1_lindroth_2okeson
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
 
Rx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2greenRx16 clinical wed_200_1_hall_2green
Rx16 clinical wed_200_1_hall_2green
 
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonickRx16 treat tues_200_1_jarvis_2fiscella_3balonick
Rx16 treat tues_200_1_jarvis_2fiscella_3balonick
 
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosalesRx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
Rx16 presummit mat-mon_200_1_bisaga_2walls_3coupland_4dupont_5garcia-rosales
 
Rx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_groupRx16 vs claad_tues_800_group
Rx16 vs claad_tues_800_group
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Rx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisherRx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisher
 
Rx16 vs ama_tues_800_harris
Rx16 vs ama_tues_800_harrisRx16 vs ama_tues_800_harris
Rx16 vs ama_tues_800_harris
 
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranRevised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
 
Rx16 federal visionsession_200
Rx16 federal visionsession_200Rx16 federal visionsession_200
Rx16 federal visionsession_200
 
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conoverRx16 advocacy tues_330_1_olsen_2raymond_3conover
Rx16 advocacy tues_330_1_olsen_2raymond_3conover
 
Rx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3greenRx16 pharma tues_330_1_painter_2lev_3green
Rx16 pharma tues_330_1_painter_2lev_3green
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Rx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3greenRx16 federal tues_200_1_gladden_2halpin_3green
Rx16 federal tues_200_1_gladden_2halpin_3green
 

Viewers also liked

Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerOPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2wallerRx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2wallerOPUNITE
 
Rx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pewRx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pewOPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliOPUNITE
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleOPUNITE
 
Web only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2badaWeb only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2badaOPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessOPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattOPUNITE
 
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyWeb only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyOPUNITE
 
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriendRx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriendOPUNITE
 
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonRx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonOPUNITE
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldOPUNITE
 
Web only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haasWeb only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haasOPUNITE
 
Rx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorinRx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorinOPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynoteOPUNITE
 

Viewers also liked (19)

Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2wallerRx16 clinical wed_1230_1_shanehsaz_2waller
Rx16 clinical wed_1230_1_shanehsaz_2waller
 
Rx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pewRx16 tpp wed_111_panel_paduda_pew
Rx16 tpp wed_111_panel_paduda_pew
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Web only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2badaWeb only rx16 treat-wed_1115_1_hudson_2bada
Web only rx16 treat-wed_1115_1_hudson_2bada
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyWeb only rx16 len wed_200_1_augustine_2napier_3darr - copy
Web only rx16 len wed_200_1_augustine_2napier_3darr - copy
 
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriendRx16 tpp tues_330_1_gavin_2saddy_3gastfriend
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
 
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeonRx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
Rx16 prev wed_1115_1_napier_2justice_3phillips_4sturgeon
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
 
Web only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haasWeb only rx16 len wed_1230_1_daugherty_2baier-haas
Web only rx16 len wed_1230_1_daugherty_2baier-haas
 
Rx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorinRx16 federal wed_1230_1_kelly_2bohn-killorin
Rx16 federal wed_1230_1_kelly_2bohn-killorin
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 

Similar to Rx16 tpp wed_200_group

Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbell
Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbellRx15 treat tues_330_1_manns_2weiss_3ghitza_4campbell
Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbellOPUNITE
 
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexanderRx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexanderOPUNITE
 
Rx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notesRx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notesOPUNITE
 
Rx15 pdmp wed_1115_1_kreiner_2ringwalt
Rx15 pdmp wed_1115_1_kreiner_2ringwaltRx15 pdmp wed_1115_1_kreiner_2ringwalt
Rx15 pdmp wed_1115_1_kreiner_2ringwaltOPUNITE
 
Rx15 treat wed_1230_1_gitlow_2gastfriend
Rx15 treat wed_1230_1_gitlow_2gastfriendRx15 treat wed_1230_1_gitlow_2gastfriend
Rx15 treat wed_1230_1_gitlow_2gastfriendOPUNITE
 
Rx16 clinical tues_1115_group
Rx16 clinical tues_1115_groupRx16 clinical tues_1115_group
Rx16 clinical tues_1115_groupOPUNITE
 
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...University of Michigan Injury Center
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaOPUNITE
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaOPUNITE
 
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonan
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonanRx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonan
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonanOPUNITE
 
2016: Considerations on Polypharmacy and Adverse Drug Events-Watanabe
2016: Considerations on Polypharmacy and Adverse Drug Events-Watanabe2016: Considerations on Polypharmacy and Adverse Drug Events-Watanabe
2016: Considerations on Polypharmacy and Adverse Drug Events-WatanabeSDGWEP
 
Characteristics and Outcomes of Adult Opiate Users in Abstinence-Based Resid...
Characteristics and Outcomes of Adult Opiate Users in Abstinence-Based  Resid...Characteristics and Outcomes of Adult Opiate Users in Abstinence-Based  Resid...
Characteristics and Outcomes of Adult Opiate Users in Abstinence-Based Resid...Siobhan Morse
 
20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.ppt20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.pptShirazKhokhar1
 
Harm reduction on a large scale
Harm reduction on a large scaleHarm reduction on a large scale
Harm reduction on a large scalePaul Coelho, MD
 

Similar to Rx16 tpp wed_200_group (20)

Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbell
Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbellRx15 treat tues_330_1_manns_2weiss_3ghitza_4campbell
Rx15 treat tues_330_1_manns_2weiss_3ghitza_4campbell
 
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexanderRx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
Rx16 adv tues_1115_1_seymourhsu_2baird_3cochran_4hartung_5alexander
 
Rx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notesRx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notes
 
Rx15 pdmp wed_1115_1_kreiner_2ringwalt
Rx15 pdmp wed_1115_1_kreiner_2ringwaltRx15 pdmp wed_1115_1_kreiner_2ringwalt
Rx15 pdmp wed_1115_1_kreiner_2ringwalt
 
FMCC 2016 Curbing Rx Drug Abuse Plenary by Sarah Chouinard
FMCC 2016 Curbing Rx Drug Abuse Plenary by Sarah ChouinardFMCC 2016 Curbing Rx Drug Abuse Plenary by Sarah Chouinard
FMCC 2016 Curbing Rx Drug Abuse Plenary by Sarah Chouinard
 
Prescribing Opioids in the ED
Prescribing Opioids in the EDPrescribing Opioids in the ED
Prescribing Opioids in the ED
 
Rx15 treat wed_1230_1_gitlow_2gastfriend
Rx15 treat wed_1230_1_gitlow_2gastfriendRx15 treat wed_1230_1_gitlow_2gastfriend
Rx15 treat wed_1230_1_gitlow_2gastfriend
 
Rx16 clinical tues_1115_group
Rx16 clinical tues_1115_groupRx16 clinical tues_1115_group
Rx16 clinical tues_1115_group
 
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
Group Health Risk Reduction Initiatives: Can Opioid Dose Reduction Reduce Har...
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
 
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahanaRx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
Rx15 ea wed_1230_1_frattaroli_2kolodny_3chan_4cahana
 
Moving Opioid Addiction Treatment Into Primary Medical Care
Moving Opioid Addiction Treatment Into Primary Medical CareMoving Opioid Addiction Treatment Into Primary Medical Care
Moving Opioid Addiction Treatment Into Primary Medical Care
 
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonan
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonanRx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonan
Rx15 clinical tues_1115_1_porathwaller-robeson_2fan-lewis-noonan
 
2016: Considerations on Polypharmacy and Adverse Drug Events-Watanabe
2016: Considerations on Polypharmacy and Adverse Drug Events-Watanabe2016: Considerations on Polypharmacy and Adverse Drug Events-Watanabe
2016: Considerations on Polypharmacy and Adverse Drug Events-Watanabe
 
Screening, Brief Intervention and Referral to Treatment (SBIRT)
Screening, Brief Intervention and Referral to Treatment (SBIRT)Screening, Brief Intervention and Referral to Treatment (SBIRT)
Screening, Brief Intervention and Referral to Treatment (SBIRT)
 
Shanahan intro sbirt basics ss
Shanahan intro  sbirt basics ssShanahan intro  sbirt basics ss
Shanahan intro sbirt basics ss
 
Twillman preventing rx abuse
Twillman preventing rx abuseTwillman preventing rx abuse
Twillman preventing rx abuse
 
Characteristics and Outcomes of Adult Opiate Users in Abstinence-Based Resid...
Characteristics and Outcomes of Adult Opiate Users in Abstinence-Based  Resid...Characteristics and Outcomes of Adult Opiate Users in Abstinence-Based  Resid...
Characteristics and Outcomes of Adult Opiate Users in Abstinence-Based Resid...
 
20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.ppt20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.ppt
 
Harm reduction on a large scale
Harm reduction on a large scaleHarm reduction on a large scale
Harm reduction on a large scale
 

Recently uploaded

Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?bkling
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...saminamagar
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxvirengeeta
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...saminamagar
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 

Recently uploaded (20)

Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptx
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 

Rx16 tpp wed_200_group

  • 1. Turning Off the Faucet from Above: Health Plan Involvement in Safe Prescribing Presenters: • Roneet Lev, MD, Director of Operations, Scripps Mercy Hospital Emergency Department, and Chair, San Diego County (CA) Rx Drug Abuse Medical Task Force • Daniel Calac, MD, FAAP, Chief Medical Officer, Indian Health Council, Inc. • Margaret Mendes, PharmD, Program Director, Academic Detailing Service, VA Desert Pacific Healthcare Network • George Scolari, Behavioral Health Program Manager, Community Health Group Third-Party Payer Track Moderator: Mark D. Birdwhistell, MPA, Vice President for Administration and External Affairs, University of Kentucky HealthCare
  • 2. Disclosures Daniel Calac, MD, FAAP; Roneet Lev, MD; Margaret Mendes, PharmD; George Scolari; and Mark D. Birdwhistell, MPA, have disclosed no relevant, real, or apparent personal or professional financial relationships with proprietary entities that produce healthcare goods and services.
  • 3. Disclosures • All planners/managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. • The following planners/managers have the following to disclose: – John J. Dreyzehner, MD, MPH, FACOEM – Ownership interest: Starfish Health (spouse) – Robert DuPont – Employment: Bensinger, DuPont & Associates-Prescription Drug Research Center
  • 4. Learning Objectives 1. Describe strategies to engage health plans in safe prescribing efforts. 2. Identify some red flag medications and combinations that are key to safe prescribing. 3. Outline some health plan policies that can be used for safe prescribing. 4. Provide accurate and appropriate counsel as part of the treatment team.
  • 5. Roneet Lev, MD, Director of Operations, Scripps Mercy Hospital San Diego Chair, San Diego Prescription Drug Abuse MedicalTask Force DanielCalac, MD, Chief Medical Officer, Indian Health Council, Inc Margaret Mendes Pharm D, Program Director,VA San Diego Healthcare System George Scolari, Behavioral Health Program Manager,Community Health Group
  • 6. VA Health Care The San Diego Medical Task Force and Death Diaries Community Health Group 1 3 4 2 Indian Health Council 5 Health Plan Recommendations
  • 7. San Diego Death Diaries Medical Examiner and PDMP Data Results
  • 8.  Facilitator  DEA  Emergency Physicians  Primary Care  Pain Management  Addiction Specialists  PharmacyAssociation  HospitalAssociation  Dental Association  PsychiatricAssociation  Pediatric Association  Kaiser  Scripps  Sharp  Community Clinics  VA  Military  Palomar Pomerado  Indian Health  Methadone Clinic
  • 9.  ME Data • 254 deaths with prescriptions as cause of death • Could be with alcohol, illicit, over the counter  PDMP Data • Does Not Include  VA  Balboa Naval Hospital  Methadone Clinics  Inpatient hospitals 186 68 254 Prescription Related Deaths in San Diego 2013 CURES Data No CURES
  • 11. 11 2.8 1.6 68.8 0 10 20 30 40 50 60 70 80 California San Diego San Diego Deaths 2013 Census 38.3 million 3.2 million 254 Patients with Rx 7,057,000 816,372 186 Chronic Use 200,080 13,567 128
  • 12. 12 PDMP Match (3) 6% PDMP Match + Doctor Shopper (3) 7% PMDP Match + Doctor Shopper + Illicit (1) 2% No Recent Methadone Rx (3) 7% No Methadone on PDMP (24) 52% No PDMP Data (12) 26% PDMP Match (3) PDMP Match + Doctor Shopper (3) PMDP Match + Doctor Shopper + Illicit (1) No Recent Methadone Rx (3) No Methadone on PDMP (24)  46 deaths  Number One drug to cause a single medication related death  85% (39) of Deaths Rx from outside PDMP system  100% deaths (7) from PDMP system from primary care
  • 13.  All PDMP Reports – 54% (100 patients)  ME Deaths – 21% (55) 39 16 Opioids + Benzodiazepines ME Reports – 55 patients PDMP Match No Match 100 86 PDMP Reports with Opioid + Benzodiazepine Combination Opioid + Benzo No Combination 13
  • 14.  52 Patients (28% of all PDMP Reports)were Doctor Shoppers  “The Heavy Half” = Received 51% of all Rx  50/50 Male/Female 28% 72% % Doctor Shoppers Doctor Shopper Regular Patient 14
  • 15.  Emergency Department Guidelines  Urgent Care Guidelines  Medication Agreements  Treatment Guidelines  Interdisciplinary Conferences  Educational Outreach  Magazine Publications  Case Discussions  Media Outreach  Further Research  Medical Examiner Feedback to Physicians
  • 16.  Lev, R et al “A description of Medical Examiner prescription –related deaths and prescription drug monitoring program data” American Journal of Emergency Medicine. December 2015.  Lev, R et al “Methadone Deaths Compared to All Prescription Related Deaths” Forensic Science International.2015  Lev, R et al “Who is prescribing controlled medications to patients who die from prescription drug abuse?” AmericanJournal of Emergency Medicine.Oct 2015. 16
  • 18. Daniel Calac, MD Chief Medical Officer Indian Health Council, Inc Funded by the National Institutes for Health and the Indian Health Service
  • 19.
  • 20.
  • 22.
  • 23.
  • 24. Study Goal: to reduce availability and misuse of prescription pain pills in a rural tribal community Hypotheses: To use focused community interventions to:  1) Create convenient options for community members to reduce availability of non-prescribed use;  2) Demonstrate feasibility of a culturally tailored and environmentally sound drug disposal system in American Indian communities; and  3) Change norms around giving away one’s prescription pain pills to family members or friends.
  • 25.  Created in 2008 to address rising prescription pain medication misuse/abuse  Use a multidisciplinary approach which addresses the physical, psychological and social issues associated with chronic pain conditions  Hold patient and provider accountable for use of opioid medications for chronic health
  • 26.  Updated prescribing practices and policies in IHC medical manual  Implement a Pain Agreement  Conduct a initial assessment ▪ Formulate a treatment plan  Treatment plan includes other modalities ▪ Acupuncture, group therapy, chiropractics, physical therapy, nutrition education
  • 27.  Set a maximum number of 200mg pill/month of any one opioids; set a maximum daily morphine equivalent dosage at 200mg  Conduct Urine Drug Screens  Conduct a CURES report  Administer pain questionnaires
  • 28. Conduct initial evaluation • History and physical examination • Lab work ordered • Screen for abuse potential using SOAAP-R • Run CURES report to check for recent opioid activity elsewhere Pain Agreement • Provider creates a plan that includes other modalities • Acupuncture, group therapy, chiropractics, physical therapy, nutrition education • Patient and provider sign agreement, and a copy of the agreement is given to the patient • Patient conducts additional assessments with other modalities Follow up • At subsequent visits, patient leaves a urine specimen for a drug screen • Pain questionnaire • Review Pain Agreement
  • 29.  Training IHC providers on safe prescribing  No longer prescribing soma (Carisoprodol)  Limit opioid formulary to MS Contin, Oxycontin, combination analgesics
  • 30.  Interviewing tribal leaders about prescription drug disposal practices and barriers to implementation  Conducting focus groups on disposal methods  Conducting pill take-back events  Establishing permanent drop-boxes
  • 31.  Daniel Calac, MD, dcalac@indianhealth.com  Tony Luna, MA, tluna@indianhealth.com  Roland Moore, PhD, roland@prev.org  Rick Mcgaffigan, MA, rmcgaffigan@prev.org
  • 32. Margaret Mendes, Pharm.D. Director, VISN 22 Academic Detailing Service
  • 33.  Discuss risks with opioids and benzodiazepines  RecognizeVeteran patients at increased risk  DescribeVA policies and processes to reduce combination  Show success inVA  Discuss future education on benzodiazepine safety 33
  • 34.  After opioids, benzodiazepines are drug class most commonly involved in pharmaceutical OD deaths (30%) 1  In the general population benzodiazepines are class most commonly involved in an opioid-related death (30%) 1  In theVA, 50% of opioid OD deaths are on concurrent benzodiazepines2  Among opioid users, risk of death goes up with benzodiazepines in a dose-response fashion 1. Jones CM, et al. JAMA 2013;309 (70):657-659. 2. Park TW, et al. BMJ. 2015;350:h2698.
  • 35. 0 10 20 30 40 50 60 70 Opioid prescription Highest quintile of avg daily opioid use Duration of opioid use >2 months Concurrent opioids Concurrent sedative hypnotics Early opioid refills Percent(%) No MH diagnosis MH diagnosis w/o PTSD PTSD JAMA 2012; 307:940-7
  • 36. Veterans are twice as likely to die from accidental overdose compared to the non-Veteran population  Assessment of risk factors is important in ourVeteran population especially in returning combatVeterans  Psychological distress may lead to inappropriate use of opioid medications  Caution should be used in this population Bohnert AS, et al. Med Care 2011;49: 393–396
  • 37. VISN 22 Network Policy N.:2015-05: Chronic Opioid Use for Non-Malignant Pain
  • 38.
  • 39.  Education on risks of overdose  Offer naloxone kits to patients at risk of overdose
  • 40.  Patient resistance  Provider resistance  Visit time constraints and follow up  Different prescribers of the medications  Primary Care – Opioids  Mental Health – Benzodiazepines
  • 41.
  • 42.  Benzodiazepines in the elderly  Associated with significant risks: falls1, hip fractures2,3,4, sedation1, CI,1,5,6 MVA7,8, OD9,10  Benzodiazepines in dementia  Generally not recommended due to side effects. Lorazepam and oxazepam do not require oxidative metabolism in the liver and have no active metabolites therefore many clinicians prefer these agents.11  Benzodiazepines in PTSD  No efficacy to support core symptoms. Cognitive effects are concerning.12  Insomnia education  50% increase in overall mortality rates associated with long-term benzodiazepine use.13  Promoting non-pharmacological treatment first  Cognitive BehavioralTherapy (CBT), CBT for Insomnia, relaxation therapy, supportive therapy
  • 43. 1. Glass J, et al. BMJ. 2005;331(7526):1169. 2. Ray WA, et al. JAMA. 1989. 262(23):3303-3307. 3. Wang PS, et al. Am J Psychiatry. 2001;158(6):892-8. 4. Chang CM, et al. Am J Geriatr Psychiatry. 2008;16(8):686-92. 5. Paterniti S, et al. J Clin Psychopharmacol. 2002;22(3):285-93. 6. Billoti de Gage S, et al. BMJ. 2012. 345:e6231. 7. Ray WA, et al. Am J Epidemiology.1992;136(7):873-83. 8. Hemmelgarn B, et al. JAMA. 1997;278(1):27-31. 9. Jones CM, et al. JAMA 2013;309(70):657-659. 10. ParkTW, et al. BMJ. 2015;350:h2698. 11. Rabins PV, et al. APA Practice Guideline forTreatment of Patients with Alzheimer’s Disease and other dementias. 12. VA/DoD 2010 Practice Guidelines for Management of PTSD. www.healquality.va.gov 13. Kripke DF, et al. 2012 BMJ open 2 , e000850.
  • 44. George Scolari, Behavioral Health Program Manager Community Health Group Chair, Healthy San Diego Behavioral HealthWork Group
  • 45.  Formed in 1998, Healthy San Diego is the umbrella in which 5 Medicaid (Medi-Cal) Managed Care Plan’s operate in San Diego.  Care1st, Community Health Group, Health Net, Kaiser Permanente & Molina Healthcare.  The Healthy San Diego Behavioral Health Work Group was formed in 1998 when Specialty Mental Health was contractually carved out of Medi-Cal Managed Care Plans in California.
  • 46.  Dr. Roneet Lev, Chair of the San Diego Prescription Drug Abuse MedicalTask Force, presented “San Diego Death Diaries” to Community Health Group’s Pharmacy and Therapeutics Committee Meeting.  The Committee elected to look at “Red Flag” medications and combinations within Community Health Group’s utilization data.
  • 47.  HolyTrinity (opioid, benzodiazepine, and carisoprodol)  Benzodiazepines Plus Opioids  Soma (carisoprodol)  Ambien (Zolpidem) – long term  Xanax – long term  Long Acting Opioids – by ED provider  Methadone – by Primary Care
  • 48.
  • 49.  Community Health Group is in the process of implementing a pain management specialty restriction on methadone prescriptions.  CHG’s Chief Medical Officer and Pharmacy Director had a conversation with an “outlier” prescriber who is not a pain management specialist.  CHG’s P&T voted to remove Soma from formulary.  Safe Prescribing Guide developed by the Healthy San Diego Behavioral HealthWork Group.
  • 50.  Chronic, non-cancer pain management by pain management specialists or in consultation with pain management specialists  Prior authorization and utilization management edits such as:  Quantity and fill limits,  Formulary management,  Provider restrictions  Concurrent use edits.
  • 51.  Use of treatment plans to include assessment of pain; treatment modalities considered, tried, failed; treatment goals; medication necessary to manage pain.  Use of a pain contract between prescriber and member.  Restrict members to one prescriber.  Restrict members to one pharmacy.  Random drug screens.  Regular review of utilization management reports based on members, prescribers, and pharmacies.  Recommend providers check CURES.
  • 52.  Review utilization of the “HolyTrinity” use among CHG members.  Review data by prescribers.  Address utilization with “outliers”.  Work on utilization management edits – will have to address strategically since this is likely to affect many providers and members.  Collaborate with other San Diego Medi-Cal Managed Care Plan’s (Healthy San Diego) .
  • 53.
  • 54. Promote PDMP Use Promote Utilization of Drug Screens Use Medication Agreements Education Formulary Changes Prior Authorization Provider Restriction Alternate PainTreatment Modality Join One San DiegoVision
  • 55. One Provider,One Pharmacist Use CURES (PDMP) MedicationAgreement No Opioid + Benzodiazepines Honor EmergencyGuidelines
  • 56.  Benzodiazepine plus Opioids – avoid combination  Soma (Carisoprodol) – off formulary  Methadone– restricted provider  Xanax – non formulary  High Dose Morphine Equivalent- prior authorization for new start > 90 MME  New Start Opioids – prior authorization for > 2-3 months  Acute Prescriptions – limit to 30 tablets  Feedback to providers after EmergencyVisit
  • 57.  Federal  Patient Satisfaction is Obstacle to Safe Prescribing  Do not link money with satisfaction scores for doctors  CURES gold standard: Universal, RealTime, Actively Managed  State  Data comparison for state  Education Databank  Law enforcement allowed to assist with court mandated rehabilitation, allow PDMP access  Pain CME, not biased towards pharmaceutical  Local  Health Plan Best Practices  Feedback from Medical Examiner to Provider  Pediatrician involved in prevention  Unified Media Message
  • 58. Turning Off the Faucet from Above: Health Plan Involvement in Safe Prescribing Presenters: • Roneet Lev, MD, Director of Operations, Scripps Mercy Hospital Emergency Department, and Chair, San Diego County (CA) Rx Drug Abuse Medical Task Force • Daniel Calac, MD, FAAP, Chief Medical Officer, Indian Health Council, Inc. • Margaret Mendes, PharmD, Program Director, Academic Detailing Service, VA Desert Pacific Healthcare Network • George Scolari, Behavioral Health Program Manager, Community Health Group Third-Party Payer Track Moderator: Mark D. Birdwhistell, MPA, Vice President for Administration and External Affairs, University of Kentucky HealthCare

Editor's Notes

  1. What else would you add?
  2. Death Diaries
  3. Indian Health Council has been existence for over forty years. It has had some meager beginnings that began with the Dept of Navy providing some basic dental services and medical care from the small wood building located down the road on Golsh.
  4. IHC provides care to 9 consortia tribes along the Hwy 76 Corridor and its service are comprised North San Diego County, nearly 200 square miles and a population of 300,000. The organization has had several locations that include a now renovated taco shop 6 miles down the road, to the 8000 sq ft structure across the street to the now state of the art 50,000 sq ft facility
  5. IHC is a 501 3c organization that operates on a 20 million dollar budget. As IHS provides 60 cents on the dollar, IHC has a vigorous grant writing operation that allows enhanced services to be provided to its consortia members, including the Pill Take Back Project. IHC is accredited by the prestigious Accreditation Associated for Ambulatory Health Care Inc. (AAAHC)
  6. IHC provides provides primary care to the community. There are some speciality services that include Cardiology Consult, Acupuncture, Podiatry, Obstetric/Gynecology, Ophthalmology, Internal Medicine and Pediatrics. There are over 20,000 visits per year for clients utilizing IHC as their medical home. There are 6 Full time providers that include an Internal Medicine/Pediatrician, Two Family Practice providers, two Physician Assistants, and One Nurse Practitioner. The client chart is maintained electronically with third party NextGen EMR that was installed in 2011. Additioanally, population management is monitored with i2i extraction software to enhance targeted therapeutic strategies. Hours of operation are 800-630 M-F at the Main site in Rincon and 8-430 MWF at the Satellite Clinic in Santa Ysabel. We also provide: Diabeties care for over 300 persons complete preventative dental care, including pedondontic, orthodontics, and periodontal behavioral health services, including individual and family counseling, substance abuse counseling Traditional medicine – sweat lodge for clients in recovery Tribal family services that promotes reunification and conflict resolution for families
  7. This slide details how Veterans with MH disorders and PTSD are at increased risk of high-risk opioid use and adverse clinical outcomes. This was based on a study of Iraq and Afghanistan veterans who received a new non-cancer-pain diagnosis within 1 year of VA entry were followed x 1 yr to evaluate whether an opioid was prescribed for 20 or more consecutive days. Patients with MH disorders were significantly more likely to receive opioids than veterans without a MH diagnosis. Veterans with PTSD were significantly more likely to be in the highest quintile for dose, receive more than 1 type of opioid concurrently, receive concurrent sedative hypnotics including benzos, and obtain early opioid refills than Veterans without a MH diagnoses.
  8. Here are a list of red flag medications: The “Holy Trinity” are: Percocet Soma Xanax Sleep aids are not meant for chronic use. Ambien is the number one problematic medication for physicians who are addicted. Xanax is intended for short term use only, not a life long prescription. Soma should be taken off the formulary. Soma does not provide muscle relaxation, and does cause death and addiction.